Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Emerging photodynamic/sonodynamic therapies for urological

<< Previous

Bullboard Posts

Next >>

Comment by ScienceFirston Oct 10, 2022 8:41am

148 Views

Post# 35015500

RE:Emerging photodynamic/sonodynamic therapies for urological

Nice catch Oden6570.

Again, TLD1433 is mentioned. And that Chinese researchers acknowledge our work.

Published: 04 October 2022

TLD1433, a ruthenium polypyridine complex, has currently entered into a phase II trial for treating NMIBC with PDT in the USA and Canada (NCT03945162). The photophysical features of the ruthenium center extend the excited state lifetime of the transition metal complex and enable it to function through oxygen-independent type I reaction [189]. The development and translation process of TLD1433, which took 6 years from the bench to a clinical trial, has many highlights to reference for the scientists, clinicians, industrial partners and investors who are working on advancing PDT/SDT to clinical translation [190].

Funding

This work was supported by the National Natural Science Foundation of China (Grant No. 11905161), the Hubei Provincial Natural Science Foundation of China (Grant No. 2021CFB040), the Health Commission of Hubei Province scientific research project (Grant No. WJ2021Q041), and the Program of Excellent Doctoral (Postdoctoral) of Zhongnan Hospital of Wuhan University (Grant Nos. ZNYB2020026, ZNYB2019016).

<< Previous

Bullboard Posts

Next >>

Understanding Implied Volatility in Options Trading